{"url_path":"/sec/fth/10-k/2026/item-16","section_key":"item-16","section_title":"Item 16 Form 10-K Summary.","topic":"sec","document":{"doc_type":"10-K/A","doc_date":"2026-06-02","source_url":"https://www.sec.gov/Archives/edgar/data/1829802/0001193125-26-252637-index.html","accession_number":"0001193125-26-252637","cik":"0001829802","ticker":"FTH","issuer_name":"Faeth Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1829802/0001193125-26-252637-index.html","primary_entity_key":"0001829802","primary_entity_name":"Sensei Biotherapeutics, Inc."},"word_count":70,"has_tables":true,"body_markdown":"Item 16. Form 10-K Summary.\n\nNone.\n\n \n\n46\n\n##### Table of Contents\n\nSIGNATURES\n\nPursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Amendment No. 1 to be signed on its behalf by the undersigned, thereunto duly authorized.\n\n \n\n \n\n \nSensei Biotherapeutics, Inc.\n\nDate: June 2, 2026\n \n\n \nBy:\n \n/s/ Christopher W. Gerry\n\n \n\n \n\n \nChristopher W. Gerry\n\n \n\n \n\n \nPresident and General Counsel\n\n \n\n47"}